References
- Alcaide, F., Carratala, J., Liiiares, J., Gudiol, F. and Martin, R. (1996) "In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin—dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients", Antimicrob. Agents Chemot her. 40, 2117–2120.
- Naqvi, B., Dorsky, D., Ali, S.A., Feingold, J.M., Edwards, R.L., Bona, RD., et al. (2001) "Efficacy of clarithromycin in preventing viridans streptococcal bacteremia following autologous stem cell transplantation", Infection 29, 201–204.
- Apseloff, G., Foulds, G., LaBoy-Goral, L., Willavize, S. and Vincent, J. (1998) "Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers", J. Clin. Pharmacol. 38, 830–835.
- Apseloff, G., Fluids, G., LaBoy-Goral, L., Kraut, E. and Vincent, J. (1996) "Severe neutropenia caused by recommended prophylactic doses of rifabutin", Lancet 348, 685.
- McWhinney, PH., Patel, S., Whiley, R.A., Hardie, J.M., Gillespie, S.H. and Kibbler, C.C. (1993) "Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin", Antimicrob. Agents Che-mother. 37, 2493–2495.
- Ohtani, H., Taninaka, C., Hanada, E., Kotaki, H., Sato, H., Sawada, Y. and Iga, T. (2000) "Comparative pharmaco-dynamic analysis of Q—T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithro-mycin in rats", Antimicrob. Agents Chemother. 44, 2630–2637.
- Uzun, C., Koten, M., Adali, M.K., Yorulmaz, F., Yagiz, R. and Karasalihoglu, A.R. (2001) "Reversible ototo)dc effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs", J. Laryngol. Otol. 115, 622–628.
- Vemulapalli, R.K., Cantey, J.R., Steed, L.L., Knapp, L. and Thielman, N.M. (2001) "Emergence of resistance to clarithro-mycin during treatment of disseminated cutaneous Myco-bacterium chelonae infection: case report and literature review", J. Infect. 43, 163–168.
- Ducins, J.A., Santolaria, S., Guirao, R., Ferrero, M., Montoro, M. and Gomollon, F. (1999) "Impact of clarithro-mycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansopta-zole, amoxycilin and darithromycin in active peptic ulcer", Aliment Pharmacol. Ther. 13, 775–780.
- Wallace, R.J., Jr., Brown, B.A. and Griffith, D.E. (1993) "Drug intolerance to high-dose clarithromycin among elderly patients", Diagn. Microbiol. Infect. Dis. 16, 215–221.
- Woo, P.C., Chow, L.W., Ma, E.S. and Yuen, KY. (1999) "Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model", Pharmacol. Res. 39, 49–54.
- Jacobi, J. (2002) "Pathophysiology of sepsis", Am. J. Health Syst. Pharm.(Suppl. 1), S3–58.
- Khadaroo, R.G. and Marshall, J.C. (2002) "ARDS and the multiple organ dysfunction syndrome: common mechanisms of a common systemic process", Crit. Care Clin. 18, 127–141.
- (2003) In: Sweetman, Sean C., ed., Martindale. The Complete Drug Reference 2003 (Pharmaceutical Press, London).
- Capellà, D., Pedros, C., Vidal, X. and Laporte, J.R. (2002) "Case-population studies in pharmacoepidemiology", Drug Safety 25(1), 7–19.
- Rodvold, K.A. (1999) "Clinical pharmacokinetics of clari-thromycin", Gin. Pharmacokinet. 37, 385–398.
- Tomioka, H., Sano, C., Sato, K. and Shimizu, T. (2002) "Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimyco-bacterial drugs against extracellular and intramacrophage Mycobacterium avium complex", Int. J. Antimicrob. Agents 19, 139–145.
- Brown, B.A., Wallace, R.J., Jr., Griffith, D.E. and Girard, W. (1995) "Clarithromycin-induced hepatotoxicity", Clin. Infect. Dis. 20, 1073–1074.